2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172583
    Neuroprotective agent 9 2757093-41-5 98%
    Neuroprotective agent 9 (compound 7) is a neuroprotective agent. Neuroprotective agent 9 is promising for research of neuron injury such as cerebral apoplexy, cerebral injury, and neuropathic pain.
    Neuroprotective agent 9
  • HY-172584
    Kv7.2/Kv7.3 modulator-1 2981435-42-9 98%
    Kv7.2/Kv7.3 modulator-1 (compound 6a) is a Kv7.2/Kv7.3 modulator with the pEC50 of 7.96 (KV7.2/3 channel opening activity). Kv7.2/Kv7.3 modulator-1 can be used for study of epilepsy, depression,brain injury and pain.
    Kv7.2/Kv7.3 modulator-1
  • HY-172585
    Kv7.2/Kv7.3 modulator-2 98%
    Kv7.2/Kv7.3 modulator-2 (compound 7d) is a Kv7.2/Kv7.3 modulator with the pEC50 of 7.42 (KV7.2/3 channel opening activity). Kv7.2/Kv7.3 modulator-2 can be used for study of epilepsy, depression,brain injury and pain.
    Kv7.2/Kv7.3 modulator-2
  • HY-172586
    GSK-3α/β-IN-1 1574354-24-7 98%
    GSK-3α/β-IN-1 is GSK-3α/β inhibitor with IC50 s of 0.265 μM and 0.255 μM for GSK-3α and GSK-3β, respectively. GSK-3α/β-IN-1 also inhibits PKA with an IC50 of 0.188 μM. GSK-3α/β-IN-1 potently inhibits cell viability of three Glioblastoma (GBM) cell lines (IC50 : 3-6 μM, 72 h) with no toxicity to human astrocytes and good metabolic stability. GSK-3α/β-IN-1 has potential CNS activity in all-human blood-brain barrier (BBB) model of GBM.
    GSK-3α/β-IN-1
  • HY-172588
    GABAA receptor modulator-7 98%
    GABAA receptor modulator-7 (compound 1m), a spiro-Barbiturate, is a GABAA receptor modulator. GABAA receptor modulator-7 reverses the action of anesthetics without affecting GABA-induced desensitization and can be used for study of antiepileptics and anxiolytics.
    GABAA receptor modulator-7
  • HY-172599
    GSK-3β probe-1 98%
    GSK-3β probe-1 (10c) is a GSK-3β probe (Ex = 341 nm, Em= 574nm, ɛ= 3.51 × 104L/mol·cm−1) and can be be used in the study of Alzheimer's disease.
    GSK-3β probe-1
  • HY-172604
    Neuroprotective agent 10 98%
    Neuroprotective agent 10 (Compound 11c) is a brain-penetrant neuroprotective agent. Neuroprotective agent 10 scavenges ABTS radicals (scavenging IC50: 9.20 μM), DPPH radicals (scavenging IC50: 7.09 μM) and superoxide anion radicals (inhibition percentage: 48.4%). Neuroprotective agent 10 also alleviates H2O2-induced oxidative damage and LPS-induced neuroinflammation with antiepileptic activity. Neuroprotective agent 10 is promising for research of epilepsy and neuroprotection.
    Neuroprotective agent 10
  • HY-172672
    Orexin 2 Receptor Agonist 3 98%
    Orexin 2 Receptor Agonist 3 (Compound 57) is an orally active and brain-penetrant orexin receptor type-2 (OX2) agonist (EC50: 2.5 nM). Orexin 2 Receptor Agonist 3 increases wakefulness in the orexin/ataxin-3 NT1 mouse model and healthy beagle dogs. Orexin 2 Receptor Agonist 3 can be used in the study of narcolepsy.
    Orexin 2 Receptor Agonist 3
  • HY-172678
    PUC-10 2095549-31-6 98%
    PUC-10 is a 5-HT6 receptor antagonist with a Ki of 14.6 nM and an IC50 of 32 nM. In silico predictions suggest that PUC-10 is orally active and can cross the blood-brain barrier. PUC-10 can induce autophagy in SH-SY5Y cells by inhibiting the mTOR pathway. PUC-10 can be used in the research of neurological disorders.
    PUC-10
  • HY-172679
    PUC-55 98%
    PUC-55 is a 5-HT6R antagonist with a Ki of 37.5 nM that induces neuronal autophagy by inhibiting the mTOR pathway. It holds potential for research in the field of neurological disorders.
    PUC-55
  • HY-172707
    DSPE-PEG1000-PP1 98%
    DSPE-PEG1000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG1000-PP1 can be used for drug delivery.
    DSPE-PEG1000-PP1
  • HY-172708
    DSPE-PEG2000-PP1 98%
    DSPE-PEG2000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG2000-PP1 can be used for drug delivery.
    DSPE-PEG2000-PP1
  • HY-172709
    DSPE-PEG5000-PP1 98%
    DSPE-PEG5000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG5000-PP1 can be used for drug delivery.
    DSPE-PEG5000-PP1
  • HY-172774
    TRPV1 antagonist 10 896584-55-7 98%
    TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist (IC50 = 33.06 nM), moderate to weak URAT1 (IC50 = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor. TRPV1 antagonist 10 has analgesic and urate-lowering effect. TRPV1 antagonist 10 can be studied for research in hyperuricemia and inflammatory pain.
    TRPV1 antagonist 10
  • HY-172782
    BuChE-IN-20 98%
    BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC50 = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease.
    BuChE-IN-20
  • HY-172816
    Carbonic anhydrase inhibitor 32 98%
    Carbonic anhydrase inhibitor 32 (compound 5B) is an orally active and selective hCA (Carbonic anhydrase ) II/VII inhibitor with the Ki values of 6.3 nM, 10.1 nM and 681 nM for hCA II, hCA VII and hCA I,respectively. Carbonic anhydrase inhibitor 32 shows neuroprotective and anticonvulsant potential by reducing mTOR activation, and raising hippocampus KCC2 levels.
    Carbonic anhydrase inhibitor 32
  • HY-172884
    MDAR-IN-1 98%
    MDAR IN-1 (Compound 5m) is a brain-penetrant inhibitor of acetylcholinesterase (AChE) and antagonist of the GluN1/GluN2B subtype of NMDAR receptor. MDAR IN-1 effectively inhibits AChE activity, enhances cholinergic neurotransmission, and blocks NMDAR, reducing excitatory neurotoxicity. MDAR IN-1 is promising for research of Alzheimer's disease.
    MDAR-IN-1
  • HY-172887
    Kv7.2/Kv7.3 activator-2 98%
    Kv7.2/Kv7.3 activator-2 is a BBB-penetrable Kv7.2/7.3 activator (EC50: 0.25 μM). Kv7.2/Kv7.3 activator-2 has good photostability. Kv7.2/Kv7.3 activator-2 has potently antiepileptic effects in maximal electroshock (MES) and sc-pentylenetetrazol (sc-PTZ)-induced acute mice seizure models.
    Kv7.2/Kv7.3 activator-2
  • HY-172898
    TRPA1-IN-4 98%
    TRPA1-IN-4 (12) is a TRPA1 inhibitor, with an IC50 of 45 nM. TRPA1-IN-4 (12) can be used in the pain research.
    TRPA1-IN-4
  • HY-172902
    RNA binder 1 98%
    RNA binder 1 (Compound 4b) is a blood-brain permeable RNA binder. RNA binder 1 can selectively bind to the G-quadruplex structure of the G4C2 repeat sequence RNA of the C9orf72 gene. RNA binder 1 significantly reduces the levels of toxic polypeptides poly(GA) and poly(GP) produced by the G4C2 repeat sequence in amyotrophic lateral sclerosis (ALS) patient-derived cells. RNA binder 1 has no significant effect on the antisense polypeptide poly(PR), showing selectivity for sense RNA. RNA binder 1 can be used in the study of ALS and frontotemporal dementia (FTD).
    RNA binder 1
Cat. No. Product Name / Synonyms Application Reactivity